MedImmune submits answers to FDA's "complete response" letter for nasal flu vaccine FluMist Aug. 26. Company hopes for approval in time for the winter flu season (1"The Pink Sheet" July 15, p. 19)...
You may also be interested in...
MedImmune could carve out a subpopulation of FluMist patients who suffer from wheezing and asthma from the proposed indication for the intranasal vaccine, the company said following receipt of a complete response letter from FDA
Pear Therapeutics’ Somryst insomnia treatment tool has become the first FDA-cleared product that was reviewed through the agency’s Software Precertification Pilot Program.
CNS specialist Neuraxpharm has struck a deal with Israel’s Panaxia to market medical cannabis products in Europe, starting in Germany.